These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 28501934)
1. CX-4945: the protein kinase CK2 inhibitor and anti-cancer drug shows anti-fungal activity. Masłyk M; Janeczko M; Martyna A; Kubiński K Mol Cell Biochem; 2017 Nov; 435(1-2):193-196. PubMed ID: 28501934 [TBL] [Abstract][Full Text] [Related]
2. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648 [TBL] [Abstract][Full Text] [Related]
3. Emodin, a natural inhibitor of protein kinase CK2, suppresses growth, hyphal development, and biofilm formation of Candida albicans. Janeczko M; Masłyk M; Kubiński K; Golczyk H Yeast; 2017 Jun; 34(6):253-265. PubMed ID: 28181315 [TBL] [Abstract][Full Text] [Related]
4. Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer. Kim HM; Jeong I; Kim HJ; Kang SK; Kwon WS; Kim TS; Park KH; Jung M; Soong J; Lin SC; Chung HC; Rha SY Anticancer Res; 2018 Nov; 38(11):6171-6180. PubMed ID: 30396934 [TBL] [Abstract][Full Text] [Related]
5. Structural basis of CX-4945 binding to human protein kinase CK2. Ferguson AD; Sheth PR; Basso AD; Paliwal S; Gray K; Fischmann TO; Le HV FEBS Lett; 2011 Jan; 585(1):104-10. PubMed ID: 21093442 [TBL] [Abstract][Full Text] [Related]
6. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance. D'Amore C; Borgo C; Sarno S; Salvi M Cell Oncol (Dordr); 2020 Dec; 43(6):1003-1016. PubMed ID: 33052585 [TBL] [Abstract][Full Text] [Related]
7. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death. Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620 [TBL] [Abstract][Full Text] [Related]
8. Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M. So KS; Kim CH; Rho JK; Kim SY; Choi YJ; Song JS; Kim WS; Choi CM; Chun YJ; Lee JC PLoS One; 2014; 9(12):e114000. PubMed ID: 25486409 [TBL] [Abstract][Full Text] [Related]
9. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia. Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886 [TBL] [Abstract][Full Text] [Related]
10. Druggability of the CK2 inhibitor CX-4945 as an anticancer drug and beyond. Kim J; Kim SH Arch Pharm Res; 2012 Aug; 35(8):1293-6. PubMed ID: 22941473 [TBL] [Abstract][Full Text] [Related]
11. Autophagy Induced by CX-4945, a Casein Kinase 2 Inhibitor, Enhances Apoptosis in Pancreatic Cancer Cell Lines. Hwang DW; So KS; Kim SC; Park KM; Lee YJ; Kim SW; Choi CM; Rho JK; Choi YJ; Lee JC Pancreas; 2017 Apr; 46(4):575-581. PubMed ID: 28196025 [TBL] [Abstract][Full Text] [Related]
12. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer. Pierre F; Chua PC; O'Brien SE; Siddiqui-Jain A; Bourbon P; Haddach M; Michaux J; Nagasawa J; Schwaebe MK; Stefan E; Vialettes A; Whitten JP; Chen TK; Darjania L; Stansfield R; Bliesath J; Drygin D; Ho C; Omori M; Proffitt C; Streiner N; Rice WG; Ryckman DM; Anderes K Mol Cell Biochem; 2011 Oct; 356(1-2):37-43. PubMed ID: 21755459 [TBL] [Abstract][Full Text] [Related]
13. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response. Chen F; Huang X; Wu M; Gou S; Hu W Cancer Lett; 2017 Jan; 385():168-178. PubMed ID: 27793693 [TBL] [Abstract][Full Text] [Related]
14. CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy. Siddiqui-Jain A; Bliesath J; Macalino D; Omori M; Huser N; Streiner N; Ho CB; Anderes K; Proffitt C; O'Brien SE; Lim JK; Von Hoff DD; Ryckman DM; Rice WG; Drygin D Mol Cancer Ther; 2012 Apr; 11(4):994-1005. PubMed ID: 22267551 [TBL] [Abstract][Full Text] [Related]
15. Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer. Battistutta R; Cozza G; Pierre F; Papinutto E; Lolli G; Sarno S; O'Brien SE; Siddiqui-Jain A; Haddach M; Anderes K; Ryckman DM; Meggio F; Pinna LA Biochemistry; 2011 Oct; 50(39):8478-88. PubMed ID: 21870818 [TBL] [Abstract][Full Text] [Related]
16. AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells. So KS; Rho JK; Choi YJ; Kim SY; Choi CM; Chun YJ; Lee JC Anticancer Res; 2015 Mar; 35(3):1537-42. PubMed ID: 25750308 [TBL] [Abstract][Full Text] [Related]
20. The MAP kinase-activated protein kinase Rck2p plays a role in rapamycin sensitivity in Saccharomyces cerevisiae and Candida albicans. Li X; Huang X; Zhao J; Zhao J; Wei Y; Jiang L FEMS Yeast Res; 2008 Aug; 8(5):715-24. PubMed ID: 18625027 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]